Clinical Trial Update: A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating autologous bone marrow-derived mononuclear cells with liberation therapy for CCSVI in relapsing-remitting multiple sclerosis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Autologous bone marrow-derived mononuclear cells (BM-MNC) with liberation therapy for CCSVI (Autologous bone marrow-derived mononuclear cells)

Snippet

Sponsor: Novo Cellular Medicine Institute LLP | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1, Phase 2 | Status: UNKNOWN